Close Menu

NEW YORK — NuProbe said on Thursday that it has granted a worldwide license for its proprietary blocker displacement amplification (BDA) technology to Oxford Nanopore Technologies.

Financial terms of the deal were not disclosed.

According to NuProbe, the BDA technology selectively amplifies low-abundance sequence variants in a background of wildtype DNA and can be combined with nanopore sequencing to enable greater detection sensitivities and quantification of somatic mutations at less than 5 percent allele frequency.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.